RecruitingNot ApplicableNCT04987086

68Ga-PSMA PET in the Renal Cell Carcinoma

A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in the Patients With Locally Advanced and Advanced Renal Cell Carcinoma


Sponsor

Xijing Hospital

Enrollment

300 participants

Start Date

Jun 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA — typically used in prostate cancer — can also detect and map metastatic renal cell carcinoma (kidney cancer) that has spread. Researchers hope this scan can provide better staging information than standard CT alone. **You may be eligible if...** - You have been diagnosed with Stage III or IV renal cell carcinoma - Your CT scan has shown suspected cancer spread - You can have the PET/CT scan performed within 6 weeks of your kidney cancer diagnosis - You are over 18 years old **You may NOT be eligible if...** - You are 18 or younger - You cannot lie flat for the duration of the PET/CT scan - You have significant kidney problems or are on hemodialysis - You have had another cancer in the past 2 years Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPSMA PET

PSMA PET may have influence on the clinical decision-making of the patients with renal cancer


Locations(9)

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

Qinghai University Affiliated Hospital

Xining, Qinghai, China

Xijing Hospital

Xi'an, Shaan'xi, China

Weinan Central Hospital

Weinan, Shaanxi, China

Shaanxi Provincial People's Hospital

Xi'an, Shaanxi, China

Xijing 986 Hospital

Xi'an, Shaanxi, China

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

Xianyang, Shaanxi, China

Affiliated Hospital of Yan'an University

Yan’an, Shaanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04987086


Related Trials